Intrinsic value of Collegium Pharmaceutical - COLL

Previous Close

$17.40

  Intrinsic Value

$0.79

stock screener

  Rating & Target

str. sell

-95%

Previous close

$17.40

 
Intrinsic value

$0.79

 
Up/down potential

-95%

 
Rating

str. sell

We calculate the intrinsic value of COLL stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.6

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  46
  70
  105
  153
  216
  296
  398
  522
  672
  849
  1,054
  1,288
  1,553
  1,848
  2,173
  2,527
  2,911
  3,324
  3,764
  4,232
  4,727
  5,248
  5,794
  6,367
  6,964
  7,587
  8,236
  8,912
  9,614
  10,343
Variable operating expenses, $m
  511
  789
  1,181
  1,713
  2,417
  3,322
  4,460
  5,856
  7,535
  9,517
  11,818
  14,449
  17,415
  20,721
  24,364
  28,341
  32,647
  37,274
  42,214
  47,461
  53,008
  58,849
  64,978
  71,395
  78,097
  85,085
  92,363
  99,935
  107,808
  115,992
Fixed operating expenses, $m
  81
  83
  84
  86
  88
  90
  92
  94
  96
  98
  100
  103
  105
  107
  109
  112
  114
  117
  119
  122
  125
  128
  130
  133
  136
  139
  142
  145
  148
  152
Total operating expenses, $m
  592
  872
  1,265
  1,799
  2,505
  3,412
  4,552
  5,950
  7,631
  9,615
  11,918
  14,552
  17,520
  20,828
  24,473
  28,453
  32,761
  37,391
  42,333
  47,583
  53,133
  58,977
  65,108
  71,528
  78,233
  85,224
  92,505
  100,080
  107,956
  116,144
Operating income, $m
  -546
  -802
  -1,160
  -1,646
  -2,289
  -3,116
  -4,154
  -5,427
  -6,959
  -8,767
  -10,864
  -13,263
  -15,967
  -18,980
  -22,301
  -25,926
  -29,850
  -34,067
  -38,569
  -43,351
  -48,406
  -53,728
  -59,314
  -65,161
  -71,269
  -77,637
  -84,269
  -91,169
  -98,343
  -105,800
EBITDA, $m
  -545
  -801
  -1,158
  -1,644
  -2,286
  -3,112
  -4,148
  -5,420
  -6,950
  -8,755
  -10,850
  -13,245
  -15,945
  -18,954
  -22,270
  -25,890
  -29,809
  -34,020
  -38,517
  -43,292
  -48,340
  -53,655
  -59,233
  -65,072
  -71,171
  -77,531
  -84,153
  -91,044
  -98,208
  -105,655
Interest expense (income), $m
  0
  0
  1
  3
  5
  7
  11
  16
  21
  29
  37
  48
  59
  73
  88
  105
  124
  145
  167
  191
  216
  243
  272
  302
  333
  366
  401
  437
  474
  513
  554
Earnings before tax, $m
  -546
  -803
  -1,162
  -1,651
  -2,296
  -3,127
  -4,169
  -5,449
  -6,988
  -8,804
  -10,912
  -13,322
  -16,040
  -19,068
  -22,406
  -26,050
  -29,994
  -34,233
  -38,760
  -43,567
  -48,649
  -54,000
  -59,616
  -65,495
  -71,635
  -78,038
  -84,706
  -91,643
  -98,857
  -106,354
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -546
  -803
  -1,162
  -1,651
  -2,296
  -3,127
  -4,169
  -5,449
  -6,988
  -8,804
  -10,912
  -13,322
  -16,040
  -19,068
  -22,406
  -26,050
  -29,994
  -34,233
  -38,760
  -43,567
  -48,649
  -54,000
  -59,616
  -65,495
  -71,635
  -78,038
  -84,706
  -91,643
  -98,857
  -106,354

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  76
  118
  176
  255
  360
  495
  664
  872
  1,122
  1,417
  1,759
  2,151
  2,593
  3,085
  3,627
  4,219
  4,860
  5,549
  6,285
  7,066
  7,891
  8,761
  9,673
  10,629
  11,626
  12,667
  13,750
  14,878
  16,050
  17,268
Adjusted assets (=assets-cash), $m
  76
  118
  176
  255
  360
  495
  664
  872
  1,122
  1,417
  1,759
  2,151
  2,593
  3,085
  3,627
  4,219
  4,860
  5,549
  6,285
  7,066
  7,891
  8,761
  9,673
  10,629
  11,626
  12,667
  13,750
  14,878
  16,050
  17,268
Revenue / Adjusted assets
  0.605
  0.593
  0.597
  0.600
  0.600
  0.598
  0.599
  0.599
  0.599
  0.599
  0.599
  0.599
  0.599
  0.599
  0.599
  0.599
  0.599
  0.599
  0.599
  0.599
  0.599
  0.599
  0.599
  0.599
  0.599
  0.599
  0.599
  0.599
  0.599
  0.599
Average production assets, $m
  3
  5
  7
  11
  15
  21
  28
  37
  47
  59
  74
  90
  109
  129
  152
  177
  204
  233
  264
  296
  331
  367
  406
  446
  487
  531
  577
  624
  673
  724
Working capital, $m
  -25
  -39
  -58
  -84
  -118
  -162
  -218
  -286
  -368
  -464
  -576
  -705
  -849
  -1,011
  -1,188
  -1,382
  -1,592
  -1,818
  -2,059
  -2,315
  -2,586
  -2,871
  -3,170
  -3,483
  -3,809
  -4,150
  -4,505
  -4,875
  -5,259
  -5,658
Total debt, $m
  20
  47
  84
  135
  202
  289
  397
  530
  690
  880
  1,099
  1,350
  1,633
  1,949
  2,296
  2,676
  3,087
  3,528
  4,000
  4,501
  5,030
  5,587
  6,172
  6,784
  7,424
  8,091
  8,785
  9,508
  10,259
  11,040
Total liabilities, $m
  49
  75
  113
  163
  231
  317
  426
  559
  719
  908
  1,128
  1,379
  1,662
  1,977
  2,325
  2,705
  3,115
  3,557
  4,028
  4,529
  5,058
  5,616
  6,201
  6,813
  7,453
  8,119
  8,814
  9,536
  10,288
  11,069
Total equity, $m
  27
  42
  63
  92
  129
  178
  238
  313
  403
  509
  632
  772
  931
  1,107
  1,302
  1,515
  1,745
  1,992
  2,256
  2,537
  2,833
  3,145
  3,473
  3,816
  4,174
  4,547
  4,936
  5,341
  5,762
  6,199
Total liabilities and equity, $m
  76
  117
  176
  255
  360
  495
  664
  872
  1,122
  1,417
  1,760
  2,151
  2,593
  3,084
  3,627
  4,220
  4,860
  5,549
  6,284
  7,066
  7,891
  8,761
  9,674
  10,629
  11,627
  12,666
  13,750
  14,877
  16,050
  17,268
Debt-to-equity ratio
  0.740
  1.110
  1.330
  1.470
  1.560
  1.620
  1.670
  1.690
  1.710
  1.730
  1.740
  1.750
  1.750
  1.760
  1.760
  1.770
  1.770
  1.770
  1.770
  1.770
  1.780
  1.780
  1.780
  1.780
  1.780
  1.780
  1.780
  1.780
  1.780
  1.780
Adjusted equity ratio
  0.359
  0.359
  0.359
  0.359
  0.359
  0.359
  0.359
  0.359
  0.359
  0.359
  0.359
  0.359
  0.359
  0.359
  0.359
  0.359
  0.359
  0.359
  0.359
  0.359
  0.359
  0.359
  0.359
  0.359
  0.359
  0.359
  0.359
  0.359
  0.359
  0.359

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -546
  -803
  -1,162
  -1,651
  -2,296
  -3,127
  -4,169
  -5,449
  -6,988
  -8,804
  -10,912
  -13,322
  -16,040
  -19,068
  -22,406
  -26,050
  -29,994
  -34,233
  -38,760
  -43,567
  -48,649
  -54,000
  -59,616
  -65,495
  -71,635
  -78,038
  -84,706
  -91,643
  -98,857
  -106,354
Depreciation, amort., depletion, $m
  1
  1
  1
  2
  3
  4
  6
  7
  9
  12
  15
  18
  22
  26
  30
  35
  41
  47
  53
  59
  66
  73
  81
  89
  97
  106
  115
  125
  135
  145
Funds from operations, $m
  -546
  -802
  -1,161
  -1,649
  -2,293
  -3,123
  -4,164
  -5,442
  -6,978
  -8,792
  -10,897
  -13,304
  -16,018
  -19,043
  -22,376
  -26,014
  -29,954
  -34,187
  -38,707
  -43,508
  -48,583
  -53,926
  -59,535
  -65,405
  -71,537
  -77,931
  -84,590
  -91,518
  -98,722
  -106,209
Change in working capital, $m
  -9
  -14
  -19
  -26
  -34
  -44
  -55
  -68
  -82
  -97
  -112
  -128
  -145
  -161
  -178
  -194
  -210
  -226
  -241
  -256
  -271
  -285
  -299
  -313
  -327
  -341
  -355
  -369
  -384
  -399
Cash from operations, $m
  -536
  -788
  -1,142
  -1,623
  -2,259
  -3,079
  -4,108
  -5,373
  -6,896
  -8,695
  -10,785
  -13,176
  -15,874
  -18,881
  -22,198
  -25,820
  -29,744
  -33,961
  -38,466
  -43,252
  -48,312
  -53,642
  -59,236
  -65,092
  -71,210
  -77,591
  -84,235
  -91,149
  -98,338
  -105,810
Maintenance CAPEX, $m
  0
  -1
  -1
  -1
  -2
  -3
  -4
  -6
  -7
  -9
  -12
  -15
  -18
  -22
  -26
  -30
  -35
  -41
  -47
  -53
  -59
  -66
  -73
  -81
  -89
  -97
  -106
  -115
  -125
  -135
New CAPEX, $m
  -1
  -2
  -2
  -3
  -4
  -6
  -7
  -9
  -10
  -12
  -14
  -16
  -19
  -21
  -23
  -25
  -27
  -29
  -31
  -33
  -35
  -36
  -38
  -40
  -42
  -44
  -45
  -47
  -49
  -51
Cash from investing activities, $m
  -1
  -3
  -3
  -4
  -6
  -9
  -11
  -15
  -17
  -21
  -26
  -31
  -37
  -43
  -49
  -55
  -62
  -70
  -78
  -86
  -94
  -102
  -111
  -121
  -131
  -141
  -151
  -162
  -174
  -186
Free cash flow, $m
  -538
  -790
  -1,145
  -1,628
  -2,266
  -3,087
  -4,120
  -5,388
  -6,914
  -8,717
  -10,811
  -13,207
  -15,910
  -18,924
  -22,247
  -25,876
  -29,806
  -34,031
  -38,544
  -43,337
  -48,406
  -53,744
  -59,348
  -65,214
  -71,341
  -77,732
  -84,387
  -91,312
  -98,512
  -105,996
Issuance/(repayment) of debt, $m
  19
  27
  37
  51
  67
  86
  109
  133
  160
  189
  220
  251
  283
  315
  348
  380
  411
  442
  471
  501
  529
  557
  585
  612
  640
  667
  695
  723
  751
  781
Issuance/(repurchase) of shares, $m
  557
  817
  1,183
  1,679
  2,334
  3,175
  4,230
  5,524
  7,077
  8,910
  11,035
  13,463
  16,199
  19,245
  22,601
  26,262
  30,224
  34,481
  39,024
  43,848
  48,945
  54,312
  59,944
  65,838
  71,993
  78,411
  85,095
  92,048
  99,277
  106,791
Cash from financing (excl. dividends), $m  
  576
  844
  1,220
  1,730
  2,401
  3,261
  4,339
  5,657
  7,237
  9,099
  11,255
  13,714
  16,482
  19,560
  22,949
  26,642
  30,635
  34,923
  39,495
  44,349
  49,474
  54,869
  60,529
  66,450
  72,633
  79,078
  85,790
  92,771
  100,028
  107,572
Total cash flow (excl. dividends), $m
  38
  54
  75
  103
  136
  174
  219
  269
  323
  382
  443
  507
  572
  637
  702
  766
  829
  891
  952
  1,011
  1,069
  1,125
  1,181
  1,236
  1,291
  1,346
  1,402
  1,459
  1,517
  1,577
Retained Cash Flow (-), $m
  -557
  -817
  -1,183
  -1,679
  -2,334
  -3,175
  -4,230
  -5,524
  -7,077
  -8,910
  -11,035
  -13,463
  -16,199
  -19,245
  -22,601
  -26,262
  -30,224
  -34,481
  -39,024
  -43,848
  -48,945
  -54,312
  -59,944
  -65,838
  -71,993
  -78,411
  -85,095
  -92,048
  -99,277
  -106,791
Prev. year cash balance distribution, $m
  87
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  -432
  -764
  -1,108
  -1,577
  -2,199
  -3,001
  -4,011
  -5,255
  -6,754
  -8,528
  -10,592
  -12,956
  -15,627
  -18,608
  -21,899
  -25,496
  -29,395
  -33,589
  -38,072
  -42,837
  -47,877
  -53,187
  -58,763
  -64,601
  -70,702
  -77,065
  -83,692
  -90,589
  -97,760
  -105,215
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  -414
  -699
  -964
  -1,298
  -1,704
  -2,178
  -2,710
  -3,284
  -3,880
  -4,471
  -5,030
  -5,529
  -5,942
  -6,247
  -6,429
  -6,479
  -6,396
  -6,186
  -5,862
  -5,443
  -4,952
  -4,413
  -3,851
  -3,290
  -2,750
  -2,248
  -1,796
  -1,402
  -1,067
  -792
Current shareholders' claim on cash, %
  14.3
  2.2
  0.4
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting. Xtampza ER is designed to provide adequate pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. ONSOLIS is a Transmucosal Immediate-Release Fentanyl (TIRF) film indicated for the management of breakthrough pain in cancer patients (BTPc), 18 years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

FINANCIAL RATIOS  of  Collegium Pharmaceutical (COLL)

Valuation Ratios
P/E Ratio -5.4
Price to Sales 255.4
Price to Book 3.8
Price to Tangible Book
Price to Cash Flow -6.8
Price to Free Cash Flow -6.5
Growth Rates
Sales Growth Rate -100%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate NaN%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio 51
Current Ratio 0
LT Debt to Equity 0.7%
Total Debt to Equity 3%
Interest Coverage 0
Management Effectiveness
Return On Assets -72.3%
Ret/ On Assets - 3 Yr. Avg. -106.6%
Return On Total Capital -81.4%
Ret/ On T. Cap. - 3 Yr. Avg. -173.5%
Return On Equity -85.5%
Return On Equity - 3 Yr. Avg. 176.1%
Asset Turnover 0
Profitability Ratios
Gross Margin 100%
Gross Margin - 3 Yr. Avg. 33.3%
EBITDA Margin -4650%
EBITDA Margin - 3 Yr. Avg. -1550%
Operating Margin -4700%
Oper. Margin - 3 Yr. Avg. -1566.7%
Pre-Tax Margin -4700%
Pre-Tax Margin - 3 Yr. Avg. -1566.7%
Net Profit Margin -4700%
Net Profit Margin - 3 Yr. Avg. -1566.7%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

COLL stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the COLL stock intrinsic value calculation we used $28.476 million for the last fiscal year's total revenue generated by Collegium Pharmaceutical. The default revenue input number comes from 0001 income statement of Collegium Pharmaceutical. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our COLL stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for COLL is calculated based on our internal credit rating of Collegium Pharmaceutical, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Collegium Pharmaceutical.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of COLL stock the variable cost ratio is equal to 1121.4%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $79 million in the base year in the intrinsic value calculation for COLL stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Collegium Pharmaceutical.

Corporate tax rate of 27% is the nominal tax rate for Collegium Pharmaceutical. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the COLL stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for COLL are equal to 7%.

Life of production assets of 4.2 years is the average useful life of capital assets used in Collegium Pharmaceutical operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for COLL is equal to -54.7%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $104.08 million for Collegium Pharmaceutical - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 33.044 million for Collegium Pharmaceutical is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Collegium Pharmaceutical at the current share price and the inputted number of shares is $0.6 billion.

RELATED COMPANIES Price Int.Val. Rating
NKTR Nektar Therape 37.65 107.89  str.buy
PFE Pfizer 42.91 34.10  hold
JNJ Johnson&Johnso 144.25 176.79  buy

COMPANY NEWS

▶ Collegium to Present at Upcoming Investor Conferences   [Nov-12-18 07:24AM  GlobeNewswire]
▶ Collegium Pharmaceutical: 3Q Earnings Snapshot   [06:21PM  Associated Press]
▶ Collegium to Present at Upcoming Investor Conference   [Sep-28-18 02:16PM  GlobeNewswire]
▶ Collegium Announces Promotion of Scott Dreyer to CCO   [Jul-10-18 07:30AM  GlobeNewswire]
▶ Collegium Announces CEO Succession   [Jun-04-18 04:01PM  GlobeNewswire]
▶ Collegium to Present at Upcoming Investor Conferences   [May-30-18 04:01PM  GlobeNewswire]
▶ Why Depomed Inc.'s Shares Soared 23.2% Higher   [May-10-18 05:40PM  Motley Fool]
▶ Collegium Pharmaceutical: 1Q Earnings Snapshot   [May-09-18 04:14PM  Associated Press]
▶ Collegium to Present at Upcoming Investor Conferences   [Mar-16-18 08:06AM  GlobeNewswire]
▶ Top Growth Stocks To Buy Now   [Mar-10-18 11:03AM  Simply Wall St.]
▶ Trump Tones Down Tariff Talk   [Mar-09-18 09:15AM  Zacks]
▶ This Biotech Flirts With Breakout Amid Battle With Opioid Makers   [Mar-08-18 04:48PM  Investor's Business Daily]
▶ Collegium Pharmaceutical posts 4Q loss   [Mar-07-18 04:09PM  Associated Press]
▶ 3 Top-Ranked Drug Stocks That Are Broker Favorites   [Jan-18-18 09:25AM  InvestorPlace]
▶ Harry Boxers three health-care stocks to watch today   [Jan-10-18 11:39AM  MarketWatch]
▶ Depomed Executes an Exit Strategy for Its Opioid Drug   [Dec-06-17 12:05PM  Motley Fool]
▶ How Two Drugmakers Rocketed On A Deal That Sees One Exit Opioid Sales   [Dec-05-17 02:29PM  Investor's Business Daily]
▶ Harry Boxer on four stocks rallying today   [Nov-16-17 02:03PM  MarketWatch]
▶ Collegium Pharmaceutical posts 3Q loss   [Nov-08-17 05:25PM  Associated Press]
▶ Collegium Receives FDA Approval for sNDA for Xtampza® ER   [Nov-07-17 08:30AM  GlobeNewswire]
▶ Collegium to Present at Upcoming Investor Conferences   [Sep-06-17 07:00AM  GlobeNewswire]
▶ Collegium Pharmaceutical posts 2Q loss   [Aug-09-17 09:16PM  Associated Press]
▶ How Endo's Opioid Pitfall Could Be A Boon For These Drugmakers   [Jun-09-17 04:07PM  Investor's Business Daily]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.